← All reports

The EU regulator maintains that Alzheimer’s drugs are beneficial despite a study questioning their effectiveness.

HealthcareLegal IssuesApr 22, 2026score 0.272 posts · 0 replies across 2 instances
The thread discusses the EU regulator's defense of Alzheimer’s drugs following a study that questions their benefits. The posts highlight a conflict between regulatory support and scientific scrutiny of the drugs' effectiveness.

Claims

The EU regulator maintains that Alzheimer’s drugs are beneficial despite a study questioning their effectiveness.
Parent: HealthcareEntity: Alzheimer’s drugsImpact: negativeDate: Apr 22, 2026Target: The effectiveness of Alzheimer’s drugs

Source posts

@[email protected]
EU regulator defends Alzheimer’s drugs after study questions benefits https://www.euractiv.com/news/eu-regulator-defends-alzheimers-drugs-after-study-questions-benefits/?utm_source=eac&utm_medium=mastodon&utm_campaign=%40euractiv_politics%40eupolicy.social
0 boosts · 0 favs · 0 replies · Apr 22, 2026
@[email protected]
EU regulator defends Alzheimer’s drugs after study questions benefits https://www.euractiv.com/news/eu-regulator-defends-alzheimers-drugs-after-study-questions-benefits/?utm_source=eac&utm_medium=mastodon&utm_campaign=%40euractiv_health%40eupolicy.social
0 boosts · 0 favs · 0 replies · Apr 22, 2026
@[email protected]
EU regulator defends Alzheimer’s drugs after study questions benefits https://www.euractiv.com/news/eu-regulator-defends-alzheimers-drugs-after-study-questions-benefits/?utm_source=eac&utm_medium=mastodon&utm_campaign=%40euractiv_agri%40eupolicy.social
0 boosts · 0 favs · 0 replies · Apr 22, 2026